… In conclusion, gefitinib does appear to be a breakthrough in the treatment of advanced
NSCLC. It is likely that its use will rapidly move from advanced late-stage disease to earlier and …

… were randomized to treatment with vinorelbine or gefitinib Citation[20]… the two treatments,
with a toxicity profile in favor of gefitinib. … of the two treatments, the use of gefitinib in unselected …

… in persons with lung cancer. Many of the principles of management relevant to gefitinib are
distinct … practical guidelines on the use of gefitinib in patients with non–small-cell lung cancer. …

… These observations suggest that by inhibiting the EGFR tyrosine kinase, gefitinib treatment
alters … Gefitinib treatment can also cause apoptosis to occur in vitro, the frequency of which …

… -cell lung cancers (NSCLC) obtaining objective response when treated with gefitinib harbour
… gefitinib efficacy. As of August 2010, four East Asian randomized phase III trials comparing …

… how NSCLC is treated. With its recent approval by the US Food and Drug Administration,
gefitinib adds to the list of recommended first-line treatments for lung cancer harboring EGFR …

… Four open-label, Phase I, dose-escalation trials determined gefitinib's safety profile in a …
receive intermittent gefitinib treatment (14 days treatment, followed by 14 days without treatment), …

… developing acute ILD associated with gefitinib treatment than with chemotherapy. The
observed incidence rate over 12 weeks was, per 1000 person-weeks, 4.5 for gefitinib and 1.7 for …

… The median duration of gefitinib treatment was 308 days (range, 14 to 1219); the median
number of 3-week cycles of chemotherapy was 4 (range, 1 to 7). Three patients in the …

… to gefitinib treatment; however, most patients develop acquired resistance to gefitinib within
a … This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical …